The goal of EDOSURE is to generate new clinical and real-world-data regarding its use in AF and VTE populations, providing physicians and patients worldwide with greater treatment assurance.

More than 100,000 patients worldwide are expected to participate in the edoxaban clinical research program, EDOSURE, which is comprised of more than 10 RCTs (randomized, controlled trials), registry and non-randomized clinical studies, including completed, ongoing and future research.

The RCTs include:

• ENGAGE AF -TIMI 48 (Effective a NticoaGulation with factor XA next GEneration in Atrial Fibrillation), in NVAF patients at moderate-to-high risk of thromboembolic events
• Hokusai-VTE (Edoxaban in Venous Thromboembolism), in patients with either acute symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE) or both
• ENSURE-AF (EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation), in AF patients undergoing electrical cardioversion
• ENTRUST-AF PCI (EdoxabaN TReatment versUS VKA in paTients with AF undergoing PCI), in AF patients undergoing percutaneous coronary intervention
• Hokusai-VTE CANCER (Edoxaban in Venous Thromboembolism Associated with Cancer), in patients with cancer and an acute VTE event
• ELDERCARE-AF (Edoxaban Low-Dose for EldeR CARE AF patients), in elderly AF patients in Japan
• ELIMINATE-AF (EvaLuatIon of edoxaban coMpared with VKA IN subjects undergoing cAThEter ablation of non-valvular Atrial Fibrillation)
• ENVISAGE-TAVI AF (EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation (TAVI) – Atrial Fibrillation)
• STABLED Study (STroke secondary prevention with catheter ABLation and EDoxaban for patients with non-valvular atrial fibrillation) in Japan
• ENRICH-AF (EdoxabaN foR IntraCranial Hemorrhage survivors with Atrial Fibrillation, an investigator initiated phase III study)

Randomized-controlled Clinical trials in AF and VTE

	Clinical Setting	First Data Disclosure
	Non valvular atrial fibrillation patients	Presented at AHA 2013 NCT00781391
	VTE patients	Presented at ESC 2013 NCT00986154
	AF patients undergoing electrical cardioversion	Presented at ESC 2016 NCT02072434
	AF patients undergoing catheter ablation	Presented at EHRA 2019 NCT02942576
	AF patients undergoing PCI	Presented at ESC 2019 NCT02866175
	AF patients undergoing transcatheter aortic valve implantation	Presented at ESC 2021 NCT02943785
	80 years or older Japanese AF patients who are ineligible for current OAC therapy	Presented at ESC 2020 NCT02801669
	Patients with VTE associated with cancer	Presented at ASH 2017 NCT02073682
	Non valvular AF patients with history of stroke	(Still ongoing) jRCTs031180249
	AF patients with history of intracranial hemorrhage	(Still ongoing) NCT03950076

In addition, EDOSURE’s global and regional registry and non-randomized clinical studies provide important real-world and clinical data about the use of edoxaban and other oral anticoagulants in everyday practice, these include:

• ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation)
• ETNA-VTE (Edoxaban Treatment in routiNe clinical prActice in patients with Venous ThromboEmbolism)
• EMIT-AF/VTE (Edoxaban Management In diagnostic and Therapeutic procedures-AF/VTE)
• Prolongation PREFER in AF (PREvention oF thromboembolic events – European Registry) in patients with AF
• ANAFIE (All Nippon AF In Elderly) Registry in Japan
• Cancer-VTE Registry in Japan
• RYOUMA Registry in Japan
• KYU-RABLE in Japan
• BPV-AF Registry in Japan

Registry and non-randomized clinical studies

	Edoxaban Treatment in routiNe clinical prActice in Patients with non-valvular Atrial Fibrillation NCT02944019 (EU) UMIN000017011 (Japan) NCT02951039 (South Korea/Taiwan) NCT03247582 (Hong Kong) NCT03247569 (Thailand)
	Prolongation PREFER in AF PREvention oF thromboembolic events-European Registry in Atrial Fibrillation DRKS00005996
	Edoxaban Treatment in routiNe clinical prActice in Patients with Venous ThromboEmbolism NCT02943993 (EU) UMIN000016387 (Japan) NCT02952599 (South Korea/Taiwan)
	All Nippon AF In Elderly registry in Japan to study NVAF in elderly patients aged 75 years and older UMIN000024006
	Edoxaban Management In diagnostic and Therapeutic procedures - AF/VTE NCT02950168
	Venous Thromboembolism (VTE) in Cancer Patients; a Multicenter Prospective Registry in Japan UMIN000024942
	Multicenter study associated with KYU-shu to evaluate the efficacy and safety of edoxaban in patients with non-valvulaR Atrial fiBriLlation undergoing cathEter ablation UMIN000029693
	Real world ablation therapy with anticoagulants in management of atrial fibrillation in Japan UMIN000026092
	Registry of antithrombotic therapy in patients with atrial fibrillation under replacement with bioprosthetic valve in Japan UMIN000034198 UMIN000034485

Through EDOSURE, we are committed to adding to the scientific body of knowledge around edoxaban in a variety of AF and VTE patients, including those who are vulnerable.